• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Neurol Neurosurg Psychiatry. Aug 2002; 73(2): 141–147.
PMCID: PMC1737988

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

Abstract

Background: In patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS), the extent of brain magnetic resonance imaging (MRI) lesion load influences the probability and time to development of clinically definite MS. Cerebral atrophy is recognised in established MS, but its time of onset and whether, in early disease, it is related to MRI lesion load or clinical outcome is less certain.

Objectives: This study investigated ventricular enlargement over one year in CIS patients and explored its relation with lesion load and clinical outcome.

Methods: A semi-automated thresholding technique for measuring ventricular volume (MIDAS) was applied to MRI scans in a cohort of 55 patients with CIS, recruited consecutively and imaged within three months of the onset of symptoms and again after one year.

Results: Clinical MS had developed after one year in 16 of 40 patients with an abnormal baseline T2 scan and 2 of 15 with a normal scan. Significant ventricular enlargement was seen in 27 of 55 patients who fulfilled the new McDonald MRI criteria for MS using all available MRI at clinical follow up (median increase 0.3 cm3, p=0.005) Significant increase in ventricular volume was also seen in the 18 of 55 patients who developed clinical MS over the follow up period (median increase 0.5 cm3, p=0.006). There were significant but modest correlations between baseline lesion measures and subsequent ventricular enlargement.

Conclusions: (1) Lesions and atrophy are both associated with early relapse leading to a diagnosis of clinical MS; (2) while lesions contribute to the development of atrophy, atrophy may also develop by other mechanisms. This suggests that MR measures have a complementary role in monitoring the course of MS, even from the earliest clinical stage.

Full Text

The Full Text of this article is available as a PDF (225K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gross KR, Tomberg TA, Kokk AA, Kaasik AE. Prognoz rasseiannogo skleroza: nekotorye komp'iuterno-tomograficheskie sopostavleniia. Zh Nevrol Psikhiatr Im S S Korsakova. 1993;93(3):32–35. [PubMed]
  • Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, McDonald WI, Miller DH. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 1995 Dec;118(Pt 6):1583–1592. [PubMed]
  • Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1999 Mar;66(3):323–330. [PMC free article] [PubMed]
  • Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging. 1997 Apr;7(2):78–80. [PubMed]
  • Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 1996 Jun;119(Pt 3):701–708. [PubMed]
  • Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, Harvey RJ, Rossor MN, Miller DH, Thompson AJ. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology. 2000 Feb 22;54(4):807–812. [PubMed]
  • Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999 Sep;46(3):296–304. [PubMed]
  • Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology. 2001 Jan 23;56(2):215–219. [PubMed]
  • Losseff NA, Kingsley DP, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler. 1996 Feb;1(4):218–222. [PubMed]
  • Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996 Dec;119(Pt 6):2009–2019. [PubMed]
  • Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci. 2000 Mar 15;174(2):85–91. [PubMed]
  • Brex Peter A, Ciccarelli Olga, O'Riordan Jonathon I, Sailer Michael, Thompson Alan J, Miller David H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002 Jan 17;346(3):158–164. [PubMed]
  • Ghezzi A, Martinelli V, Torri V, Zaffaroni M, Rodegher M, Comi G, Zibetti A, Canal N. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999 Sep;246(9):770–775. [PubMed]
  • Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, Miller DH. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 2000 Apr 25;54(8):1689–1691. [PubMed]
  • Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. [PubMed]
  • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121–127. [PubMed]
  • Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed. 1997 May;53(1):15–25. [PubMed]
  • Brex PA, Leary SM, O'Riordan JI, Miszkiel KA, Plant GT, Thompson AJ, Miller DH. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):544–547. [PMC free article] [PubMed]
  • Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 Dec;112(Pt 6):1419–1428. [PubMed]
  • Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993 Nov;34(5):661–669. [PubMed]
  • Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997 Nov;42(5):783–793. [PubMed]
  • Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997 Mar;120(Pt 3):393–399. [PubMed]
  • Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285. [PubMed]
  • van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama à Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999 Nov;46(5):747–754. [PubMed]
  • Brex PA, Gomez-Anson B, Parker GJ, Molyneux PD, Miszkiel KA, Barker GJ, MacManus DG, Davie CA, Plant GT, Miller DH. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci. 1999 Jun 15;166(1):16–22. [PubMed]
  • Brex PA, Leary SM, Plant GT, Thompson AJ, Miller DH. Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis. AJNR Am J Neuroradiol. 2001 May;22(5):947–951. [PubMed]
  • Kaiser JS, Grossman RI, Polansky M, Udupa JK, Miki Y, Galetta SL. Magnetization transfer histogram analysis of monosymptomatic episodes of neurologic dysfunction: preliminary findings. AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1043–1047. [PubMed]
  • Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1034–1038. [PubMed]
  • Chard Declan T, Parker Geoffrey J M, Griffin Colette M B, Thompson Alan J, Miller David H. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging. 2002 Mar;15(3):259–267. [PubMed]
  • Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. [PubMed]
  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. [PubMed]
  • Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999 Nov 10;53(8):1698–1704. [PubMed]
  • Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000 Nov;123(Pt 11):2256–2263. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...